Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

Therapeutic advances in medical oncology（2023）

引用 0|浏览10

暂无评分

摘要

This study was registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04280081) ClinicalTrials.gov Identifier: NCT04280081.

查看译文

关键词

HRQoL, LIBRETTO-321, PROs, RET fusion-positive NSCLC, RET fusion-positive thyroid cancer, RET-mutant MTC, Selpercatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要